D.E. Shaw & Co Portfolio holdings
D. E. Shaw & Co., L.P., founded in 1988 by David E. Shaw, a former Columbia University computer science professor, is a New York City-based global investment management firm renowned for pioneering quantitative investing, managing over $70 billion in assets as of late 2024. Starting with $28 million from Paloma Partners and private investors, the firm employs sophisticated mathematical models and proprietary algorithms—initially developed by a team of scientists and programmers—to exploit market anomalies across public and private markets, including equities, fixed income, and alternatives. Headquartered above a Greenwich Village bookstore in its early days, it now boasts over 2,500 employees across offices in North America, Europe, and Asia, led by a seven-member Executive Committee since Shaw stepped back in 2001 to focus on D. E. Shaw Research. Despite setbacks like the 1998 Russia debt crisis and the 2008 financial downturn, the firm has maintained a reputation for analytical rigor, risk management, and innovation, balancing its computational roots with discretionary strategies.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
State Street SPDR S&P 500 ETF Trust
SPY
|
+$9.6B |
| 2 |
Amazon
AMZN
|
+$1.56B |
| 3 |
NVIDIA
NVDA
|
+$1.1B |
| 4 |
Meta Platforms (Facebook)
META
|
+$924M |
| 5 |
SpaceX
SPCX
|
+$907M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Micron Technology
MU
|
+$2.17B |
| 2 |
Broadcom
AVGO
|
+$1.53B |
| 3 |
Microsoft
MSFT
|
+$1.05B |
| 4 |
TSMC
TSM
|
+$928M |
| 5 |
Texas Instruments
TXN
|
+$904M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Miscellaneous | 33.7% |
| 2 | Technology | 18.77% |
| 3 | Financials | 8.35% |
| 4 | Healthcare | 7.91% |
| 5 | Consumer Discretionary | 7.84% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | Held Since | |
|---|---|---|---|---|---|---|---|
4251
Sprott Junior Copper Miners ETF
COPJ
$139M
| $334K | ﹤0.01% |
+8,445
| New | +$357K |
2026 Q2
0 quarters
|
|
4252
PUT
CRISPR Therapeutics
CRSP
$4.83B
| $333K | ﹤0.01% |
+6,100
| New | +$322K |
2026 Q2
0 quarters
|
|
4253
Calumet Specialty Products
CLMT
$4.34B
| $333K | ﹤0.01% |
+9,235
| New | +$310K |
2026 Q2
0 quarters
|
|
4254
Schwab Fundamental US Small Company Index ETF
FNDA
$8.85B
| $332K | ﹤0.01% |
8,735
-10,490
| -55% | -$374K |
2026 Q1
1 quarter
|
|
4255
CALL
Transmedics
TMDX
$2.5B
| $332K | ﹤0.01% |
5,000
| – | – |
2024 Q2
8 quarters
|
|
4256
Lineage Inc
LINE
$7.99B
| $332K | ﹤0.01% |
+7,674
| New | +$302K |
2026 Q2
0 quarters
|
|
4257
Fidelity Enhanced Small Cap Core ETF
FESM
$6.5B
| $331K | ﹤0.01% |
6,864
-43,672
| -86% | -$1.92M |
2026 Q1
1 quarter
|
|
4258
ROBO Global Robotics & Automation Index ETF
ROBO
$1.88B
| $330K | ﹤0.01% |
3,850
-2,508
| -39% | -$206K |
2024 Q2
8 quarters
|
|
4259
Vanguard International Dividend Appreciation ETF
VIGI
$9.26B
| $329K | ﹤0.01% |
3,525
-300
| -8% | -$27.8K |
2026 Q1
1 quarter
|
|
4260
Bridgewater Bancshares
BWB
$576M
| $329K | ﹤0.01% |
15,632
-3,929
| -20% | -$74.5K |
2023 Q4
10 quarters
|
|
4261
PUT
AGNC Investment
AGNC
$10.5B
| $328K | ﹤0.01% |
30,100
+13,500
| +81% | +$142K |
2026 Q1
1 quarter
|
|
4262
CALL
PAR Technology
PAR
$752M
| $327K | ﹤0.01% |
18,800
-100
| -0.5% | -$1.44K |
2025 Q3
3 quarters
|
|
4263
iShares Residential and Multisector Real Estate ETF
REZ
$816M
| $327K | ﹤0.01% |
3,456
-1,200
| -26% | -$108K |
2024 Q4
6 quarters
|
|
4264
MFS Active Growth ETF
MFSG
$386M
| $327K | ﹤0.01% |
+10,802
| New | +$316K |
2026 Q2
0 quarters
|
|
4265
Claritev Corp
CTEV
$398M
| $327K | ﹤0.01% |
+9,580
| New | +$235K |
2026 Q2
0 quarters
|
|
4266
CALL
Keel Infrastructure Corp
KEEL
$1.38B
| $325K | ﹤0.01% |
+56,600
| New | +$243K |
2026 Q2
0 quarters
|
|
4267
CALL
Gartner
IT
$14.8B
| $324K | ﹤0.01% |
+2,500
| New | +$377K |
2026 Q2
0 quarters
|
|
4268
American Beacon GLG Natural Resources ETF
MGNR
$1.2B
| $324K | ﹤0.01% |
+6,674
| New | +$352K |
2026 Q2
0 quarters
|
|
4269
Direxion NASDAQ-100 Equal Weighted Index ETF
QQQE
$1.43B
| $323K | ﹤0.01% |
+2,647
| New | +$299K |
2026 Q2
0 quarters
|
|
4270
Kymera Therapeutics
KYMR
$9.22B
| $321K | ﹤0.01% |
+2,800
| New | +$241K |
2026 Q2
0 quarters
|
|
4271
Barings BDC
BBDC
$873M
| $321K | ﹤0.01% |
37,677
-268,200
| -88% | -$2.3M |
2026 Q1
1 quarter
|
|
4272
Niagen Bioscience
NAGE
$199M
| $319K | ﹤0.01% |
99,938
-177,443
| -64% | -$720K |
2024 Q3
7 quarters
|
|
4273
WisdomTree US MidCap Fund
EZM
$921M
| $318K | ﹤0.01% |
4,191
| – | – |
2024 Q2
8 quarters
|
|
4274
WisdomTree US High Dividend Fund
DHS
$1.63B
| $316K | ﹤0.01% |
+2,784
| New | +$310K |
2026 Q2
0 quarters
|
|
4275
Zeta Global
ZETA
$8.41B
| $316K | ﹤0.01% |
16,054
-49,445
| -75% | -$917K |
2025 Q4
2 quarters
|
|
Similar funds
D.E. Shaw & Co's Q2 2026 Portfolio in Review
As of Q2 2026, D.E. Shaw & Co held 5,360 positions worth $210B, up 26% from $166B the previous quarter. Its ten largest holdings account for 15% of the portfolio.
D.E. Shaw & Co deployed $8.31B of net new capital in Q2 2026, opening 872 new positions and adding to 1,718 existing holdings. Its largest new stake was SpaceX: 5,340,000 shares worth $912M.
By sector, the portfolio is most concentrated in Miscellaneous at 34% of assets, up from 30% a quarter earlier, followed by Technology and Financials.
On the sell side, the largest reduction was Micron Technology, an estimated $2.17B trimmed.
- D.E. Shaw & Co's largest Q2 2026 buy was SpaceX: 5,340,000 shares worth $912M.
- D.E. Shaw & Co added most to State Street SPDR S&P 500 ETF Trust in Q2 2026, an estimated $9.6B increase.
- D.E. Shaw & Co's biggest Q2 2026 reduction was Micron Technology, cutting an estimated $2.17B.
- D.E. Shaw & Co fully exited Automatic Data Processing in Q2 2026, selling an estimated $241M.
- D.E. Shaw & Co's ten largest holdings make up 15% of its $210B portfolio in Q2 2026.
- D.E. Shaw & Co opened 872 new positions and closed 527 in Q2 2026.
- D.E. Shaw & Co's portfolio value rose 26% quarter-over-quarter to $210B.
Based on D.E. Shaw & Co's 13F filing for Q2 2026, filed 14 Aug 2026.